Keep Me Logged In
Execution risk and the disruptive element of Pfizer's offer on AstraZeneca's pipeline were also taken into consideration before rebuffing the U.S. giant, Leif Johansson, chairman at AstraZeneca, tells CNBC.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2018 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by